Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's latest milestone – the granting of its second European patent, which he says is a key part of Genflow’s intellectual property strategy in the longevity and metabolic disease space. Leire explained that the patent strengthens the company’s position by providing protection not only for the composition of matter but also for specific methods of use, all focused around Sirtuin-6, a core element in the company’s technology platform. He stated, “We’re building a layer portfolio that combines property, construct, delivery method, and specific applications for human health.” The new patent covers a variant for NASH (non-alcoholic steatohepatitis), but Leire noted that the Sirtuin-6 platform has broader relevance for multiple age-related diseases, including glaucoma, sarcopenia, and other metabolic conditions. He emphasised that strong IP is essential for entering into licensing and partnership discussions with pharmaceutical companies, adding, “Without strong IP protection, there's no potential deal with pharma.” Looking ahead, Leire said that Genflow is prioritising its ongoing dog study and will soon undertake a strategic review to determine which of the many potential indications to pursue further. Visit Proactive's YouTube channel for more company interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update. #GenflowBiosciences #Longevity #BiotechNews #Sirtuin6 #MetabolicDisease #BiotechInvesting #NASH #IPStrategy #PharmaPartnerships #AgeRelatedDiseases